News
Hosted on MSN1mon
Viking Therapeutics targets 2025 Phase 3 trials for VK2735 obesity program with promising resultsCEO Brian Lian highlighted the company's progress ... aiming to broaden the company's obesity treatment pipeline. Asim Rana, Truist Securities: Asked about the timing of Phase 2 oral readout ...
ATLANTA, March 25, 2025 /PRNewswire/ -- Truist Securities announced today that Danielle Brill has joined the firm as managing director, strengthening its equity research coverage in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback